While reporting financial results for the fourth quarter on Tuesday, medical devices company AngioDynamics, Inc. (ANGO) initiated its adjusted loss and net sales guidance for the full year 2026.
For fiscal 2026, the company now projects adjusted loss in a range of $0.35 to $0.25 per share on net sales between $305 million and $310 million.
On average, three analysts polled expect the company to report a loss of $0.23 per share on net sales of $304.86 million for the year. Analysts' estimates typically exclude special items.
The company said it expects a $4.0 million to $6.0 million impact from tariffs, based on the Company's point of view on the current tariff situation, as of July 15, 2025.
For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.